Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer

SCRI Development Innovations, LLC198 enrolled

Overview

This is a retrospective medical record abstraction study. It is a review and evaluation of up to 300 metastatic breast cancer patients treated with Abraxane or other taxanes such as paclitaxel and docetaxel to determine the overall cost of care for Abraxane compared to other taxanes in the first-line metastatic cancer setting and the cost of care for Abraxane compared to other taxanes when broken down by individual components of cost. In addition, the investigators will review the following patient outcomes: response rate, duration of therapy, toxicity, and survival.

Study Type

OBSERVATIONAL

Enrollment

198

Conditions

Metastatic Breast Cancer

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients that have received Abraxane chemotherapy greater than three months from the time of chart review. * Patients that have received taxane chemotherapy greater than three months from the time of chart review.

Locations (2)

Georgia Cancer Specialists

Atlanta, Georgia, United States

Outcomes

Primary Outcomes

Describe patient demographics, disease and treatment characteristics.

Time frame: 6 months

Secondary Outcomes

Describe detailed treatment and response characteristics.

Time frame: 6 months

Describe resource utilization and cost variables.

Time frame: 6 months